Parallel Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-2
Closed 3623
2022
Q3
$0 Buy
+2
New +$110 ﹤0.01% 3635
2022
Q1
Sell
-409
Closed -$12K 3409
2021
Q4
$12K Buy
409
+9
+2% +$279 ﹤0.01% 2050
2021
Q3
$10K Hold
400
﹤0.01% 2099
2021
Q2
$14K Sell
400
-25
-6% -$976 ﹤0.01% 1878
2021
Q1
$17K Sell
425
-102
-19% -$4.69K ﹤0.01% 1684
2020
Q4
$23K Buy
527
+127
+32% +$6.26K ﹤0.01% 1424
2020
Q3
$22K Hold
400
﹤0.01% 1408
2020
Q2
$25K Hold
400
﹤0.01% 1329
2020
Q1
$20K Sell
400
-19
-5% -$1.27K ﹤0.01% 1320
2019
Q4
$33K Sell
419
-81
-16% -$4.8K ﹤0.01% 1195
2019
Q3
$24K Sell
500
-200
-29% -$10.4K ﹤0.01% 1286
2019
Q2
$37K Buy
700
+200
+40% +$11.5K ﹤0.01% 1020
2019
Q1
$26K Hold
500
﹤0.01% 1111
2018
Q4
$20K Sell
500
-200
-29% -$7.49K ﹤0.01% 1056
2018
Q3
$27K Hold
700
﹤0.01% 1042
2018
Q2
$31K Hold
700
﹤0.01% 901
2018
Q1
$34K Sell
700
-400
-36% -$22.3K 0.01% 836
2017
Q4
$43K Hold
1,100
0.01% 752
2017
Q3
$43K Hold
1,100
0.01% 736
2017
Q2
$29K Hold
1,100
0.01% 874
2017
Q1
$33K Sell
1,100
-150
-12% -$3.78K 0.01% 782
2016
Q4
$18K Buy
+1,250
New +$22K ﹤0.01% 907

Other funds holding GBT

Parallel Advisors's GBT Position: Q4 2022 in Review

Parallel Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2 shares.

Parallel Advisors first reported a position in GBT in Q4 2016 and held it in 22 quarters. The position peaked at $43K in Q4 2017. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Parallel Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 2 Global Blood Therapeutics, Inc. shares in Q4 2022.
  • Parallel Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 22 quarters.
  • Parallel Advisors's Global Blood Therapeutics, Inc. position peaked at $43K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.